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underwent a ﬁrst allo-HCT for AML at our center during Feb.
2005 - May 2013. Patient characteristics were: median age,
53 (18-74); M¼75, F¼87; MRD¼59, MUD¼67, haplo¼36;
ablative conditioning¼98, RICT/NST¼64; PBSC¼142,
BM¼20; CIBMTR risk category- high¼53, intermediate¼28,
low¼74, unknown¼7. Post-relapse therapy (PRT) was
determined by the attending physician and patient prefer-
ence. Patient characteristics, PRT, GVHD and survival were
prospectively collected. With a median follow-up for sur-
viving patients of 22.4 months, relapse of AML post-allo-HCT
occurred in 55 patients (22 MRD, 24 MUD, 9 haplo; cytoge-
netic risk 23 poor, 31 intermediate, 1 unknown) at a median
of 113 days (25-1106) post allo-HCT. Thirty-four patients
(62%) were treated with a hypometh post-relapse (17 aza-
citidine, 10 decitabine, 7 both) (12 hypometh alone, 11
combined with chemotherapy, 11 sequentially with chemo-
therapy). Median number of hypometh cycles was 2 (1-9). Of
the 23 patients that received at least 2 hypometh cycles, 14
achieved CR or CRi. DLI was administered in 15 of the 55
relapsed patients and 16 patients received a second allo-HCT.
Estimated Kaplan-Meier probability of post-relapse survival
(PRS) at 6,12 and 24months for all patients was 53%, 36% and
19% and was not signiﬁcantly different for patients who
developed any versus no PRT GVHD. However, PRS at 6 and
12months was 62% (95% CI 43-76%) and 38% (95% CI 22-54%)
in patients who received post-relapse hypomeths versus 38%
(95% CI 18-58%) and 33% (95% CI 15-53%) in patients who did
not (p¼0.063 Gehan’s test). There was no difference in PRS at
24 months. PRS > 1 year was achieved in 19 of 55 patients (9
received a second allo-HCT, 9 received DLI, 12 received a
hypometh). At the time of writing, 6 patients are alive and in
CR at a median of 49 months (10-72) post-relapse. Of the 6
patients (5 MRD, 1 MUD; cytogenetic risk 2 poor, 4 inter-
mediate), 4 received hypomeths, 3 received a second trans-
plant, 1 received DLI, and 4 have active GVHD.
Relapse post allo-HCT remains a major obstacle to long-term
survival in patients with AML. The use of hypomeths may be
associated with a prolongation of early PRS although it does
not appear to increase PRS beyond one year. PRS beyond one
year can be achieved without a second allogeneic transplant
in a minority of relapsing patients. Combination of therapy
with hypomeths and novel agents may be necessary to
impact long-term outcome.367
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Combining a CD34+ selected haplo-graft with a full graft cord
blood (CB) unit is a cell support procedure that can make
single CB available as a donor source to a larger proportion ofpatients. Early haplo-donor cell engraftment may serve as a
myeloid bridge until sustainable CB-engraftment. In addition
it has been hypothesized that haplo-derived innate anti-tu-
mor activity (e.g. NK- / gd-Tcells through other cell selection
techniques) plus CB could be a platform for multi-modal
anti-tumor activity in high-risk malignancies. The latter in
the context of omitting serotherapy. The impact of sero-
therapy-exposure on the success of "haplo-myeloid bridge to
CB engraftment" is however unknown.
Methods: Since 2009 in the UMC Utrecht 2 haplo-CB pro-
tocols were open; 1) active infection and/or known difﬁcult
engraftment without a conventional donor available: CB +
CD34+selected Haplo-id donor (5milj CD34+/kg), 2) Poor risk
malignancies, not eligible to other treatment protocols: CB +
CD19/abTCR depleted haplo-id donor (5milj CD34+/kg).
Conditioning regimens: 1st HCT busulfan (targeted cum.ex-
posure of 90mg*h/L)+ Fludarabine (Flu)+ Thymoglobulin
(ATG) in protocol 1 or Flu/Cyclophosphamide (Cy)/TBI as RIC-
alternative; 2nd HCT Treosulfan, Flu+Campath (TreoFluCamp:
protocol 1). G-CSF was given from day +7. Patients received
GvHD-profylaxis with CsA and pred 1 mg/kg. Active-ATG
levels and Campath levels were measured as described pre-
viously (Jol et al. BMT 2012). The association of serotherapy-
exposure for the endpoints overall survival (OS), non-relapse
mortality (NRM), neutrophil recovery and graft failure (GF)
was analyzed. GF was deﬁned as either "early loss of Haplo
and no engraftment of the CB" or secondary loss of both
grafts. Logrank testing was used in statistical analyses.
Results: 22 patients were included (18 protocol 1; 4 protocol
2): 20 patients received FluBu (15 ATG, 1 Campath), 1 Treo-
FluCamp and 1 FluCyTBI. Median nucleated cell dose was 4.1
x 10e7/kg (2.0-20.0). There was a cumulative incidence (CI)
of neutrophil recovery of 81% with a median of 13 days. The
CI of GFwas however 4311%. Themedian "active ATG-AUC"
(area under the curve) was 17 IU*day/L (1 pat no Campath
AUC, 1 very high AUC: 150 IU*day/L). Patients were grouped
to having no serotherapy (n¼5), a low exposure (AUC<me-
dian: n¼8), or high exposure (AUC3 median: n¼9). GF were
signiﬁcantly higher in the no serotherapy/low AUC group
(p¼0.032: Fig 1) vs. the high AUC group. 3-yr prob. of OS was
48 12% (32 17% for the no/low AUC vs. 65  17% for high
AUC, p¼0.18 ). NRM in the no/low AUC group was 5616%
versus 2214% for high-AUC (Fig.2. p¼0.21).
In conclusion: A minimum of serotherapy exposure is
required for a successful "haplo-myeloid bridge to CB
engraftment". It is doubtful whether omitting serotherapy
will have a place in haplo-CB HCT. With sufﬁcient
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high-risk group of HCT patients.368
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Background: In India, there is an urgent need to enhance the
hematopoietic stem cell transplant (HSCT) facilities. It is also
important to be certain that these procedures can be carried
out within the existing infrastructure of hospitals with
requisite expertise. Although, there is a sudden rise in
numbers of transplant centres in last 2-3 years, there is still a
lack of dedicated HSCT units equipped with special air-
handling facilities and high efﬁciency air (HEPA) ﬁlter rooms.
It is important to ascertain the safety of performing allogenic
HSCT in single rooms without HEPA ﬁlters.
Aim: To evaluate short and long term outcomes of allogenic
HSCT performed in non-HEPA ﬁltered single rooms.
Patients and Methods: We analysed ﬁrst 123 consecutive
patients, who underwent an allogenic HSCT performed in
non-HEPA ﬁltered air-conditioned single rooms with barrier
nursing over 7 years from July 2005 to August 2012. The
preferred source of stem cells was GCSF mobilised peripheral
blood stem cells (PBSC). In small donors, where PBSC was
technically difﬁcult, bone marrow was harvested under
general anaesthesia. All patients received antibacterial,
antifungal and antiviral prophylaxis. At the onset of fever,
systemic antibiotics were started. Antifungal agents were
added if fever persisted for 3 days.
Results: We present our experience of performing 123
consecutive HLA matched sibling donor allogenic trans-
plantations. Source of stem cells was peripheral blood in 105
(85.4%), bonemarrow in 16 (13.0%) and combined in 1 (0.8%),
and one died during the period conditioning regimen was
administered before infusion of stem cells. The indications
were severe aplastic anemia (SAA) 58 (47.2%), CML 16 (13%),
AML 17 (13.8%), ALL 7 (5.7%), biphenotypic AL 3 (2.4%),
thalassemia/CDA 17 (13.8%) andmyelodysplastic syndrome 4
(3.2%), PRCA 1 (0.8%). The mean age was 23.8 years (range:2.2 e 52 years, SD: 12.5 years) with 28 (22.8%) females and
95 (77.2%) males. Mean CD34 cell dose was 5.35 x 106/kg
(range: 0.7 e 10.24, SD: 2.08). Median time to neutrophil
engraftment was 10 days (range 8 e 21 days). Two patients
with thalassemia major who received bone marrow as stem
cell source did not engraft and succumbed to fungal pneu-
monia. Fever occurred in 104 (85.6%) patients for a median of
6 days (range 2 e 10 days). Systemic antibiotics were used in
all thosewho had fever and antifungals in 48 (39%) cases. The
30 day mortality was 11 (8.9%) and 100 day mortality was 17
(13.8%). There were 26 (21.1%) fatalities in total, due to failure
to engraft 2, platelet refractoriness leading to intracranial
bleed 2, VOD 2, relapse 3, graft rejection 3, acute GvHD 3,
chronic GvHD 2, infections like disseminated TB 3 and
aspergillosis 6.
Conclusion: The result of this study highlights the fact that
allogenic BMT can be performed successfully with manage-
able toxicity in majority of cases under resource crunch
settings.369
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Background: Clostridium difﬁcile infection (CDI) is one of
the leading causes of hospital-acquired infections in recent
times. Hematopoietic stem cell transplantation (HSCT) con-
fers increased risk for CDI because of prolonged hospital stay,
immunosuppression, the need to use broad spectrum anti-
biotics and a complex interplay of preparative regimen and
graft versus host disease (GVHD)-induced gut mucosal
damage. Although there have been studies describing the
epidemiology and risk factors (RF) for CDI in HSCT recipients,
there are little data regarding recurrence rate of CDI and RF
associated with recurrence in this particular patient popu-
lation, especially given the ubiquity of traditional RF for CDI
in this population.
Aim: To evaluate the recurrence rate and RF associated with
recurrent CDI in allogeneic HSCT recipients.
Design and Methods: We conducted a retrospective, single
center study of 499 allogeneic HSCT recipients transplanted
between 2005 and 2012; of these, 61 (12%) developed CDI
within 6 months prior to transplant or 2 years after trans-
plant and were included in the analysis. Recurrent CDI was
deﬁned as recurrence after appropriate treatment of ﬁrst
episode which occurred in 20 (33%) of patients. Variables
including age, antibiotic use, proton pump inhibitor use,
presence of GVHD and other patient and transplant charac-
teristics were analyzed as potential RFs for recurrence.
Results: The 61 patients had a median age of 49 yrs (range 2-
73 yrs) and M:F ratio of 1.1. 74% received myeloablative
regimen and 26% received non-myeloablative regimen for
HSCTand acute GVHDwas seen in 59% of patients. Once-year
incidence of CDI recurrence in our study was 31% compared
tow20% recurrence in other series. Fine and Gray regression
analysis identiﬁed the number of antecedent antibiotics
other than those used to treat CDI as the only signiﬁcant RF
for recurrence (Hazard ratio (HR) 1.96, 95% Conﬁdence In-
terval (CI) 1.09-3.52, P ¼ 0.025). Most recurrences occurred
